MAJOR ARTICLE Antimicrobial Resistance Trends and Outbreak Frequency in United States Hospitals Daniel J. Diekema, 1,2 Bonnie J. BootsMiller, 1,2 Thomas E. Vaughn, 3 Robert F. Woolson, 3 Jon W. Yankey, 1 Erika J. Ernst, 4 Stephen D. Flach, 1,2,5 Marcia M. Ward, 3 Carrie L. J. Franciscus, 1,2 Michael A. Pfaller, 2,3 and Bradley N. Doebbeling 1,2,3 1 Iowa City Veterans Affairs Medical Center and 2 Departments of Internal Medicine and Pathology, Carver College of Medicine, 3 Department of Epidemiology, College of Public Health, 4 College of Pharmacy, and 5 Public Policy Center, University of Iowa, Iowa City, Iowa We assessed resistance rates and trends for important antimicrobial-resistant pathogens (oxacillin-resistant Staphylococcus aureus [ORSA], vancomycin-resistant Enterococcus species [VRE], ceftazidime-resistant Klebsiella species [K-ESBL], and ciprofloxacin-resistant Escherichia coli [QREC]), the frequency of outbreaks of infection with these resistant pathogens, and the measures taken to control resistance in a stratified national sample of 670 hospitals. Four hundred ninety-four (74%) of 670 surveys were returned. Resistance rates were highest for ORSA (36%), followed by VRE (10%), QREC (6%), and K-ESBL (5%). Two-thirds of hospitals reported increasing ORSA rates, whereas only 4% reported decreasing rates, and 24% reported ORSA outbreaks within the previous year. Most hospitals (87%) reported having implemented measures to rapidly detect resistance, but only 50% reported having provided appropriate resources for antimicrobial resistance prevention (53%) or having implemented antimicrobial use guidelines (60%). The most common resistant pathogen in US hospitals is ORSA, which accounts for many recognized outbreaks and is increasing in frequency in most facilities. Current practices to prevent and control antimicrobial resistance are inadequate. Health care associated (nosocomial) infections affect 2,000,000 persons admitted to US acute care hospitals each year [1]. Increasingly, nosocomial pathogens are resistant to antimicrobial agents current surveillance reveals steadily increasing rates of resistance to oxacillin among Staphylococcus aureus and to vancomycin among Enterococcus species [2 5]. The recent recovery of vancomycin-resistant S. aureus from patients in Michigan and Pennsylvania lends new urgency to efforts to prevent and control antimicrobial resistance [6, 7]. Although existing antimicrobial resistance surveil- Received 2 June 2003; accepted 25 August 2003; electronically published 8 December 2003. Financial support: Department of Veterans Affairs, Health Services Research and Development Service (Epidemiology Merit Review grant). Reprints or correspondence: Dr. Daniel J. Diekema, Dept. of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Dr., Iowa City, IA 52242 (daniel-diekema@uiowa.edu). Clinical Infectious Diseases 2004; 38:78 85 2004 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2004/3801-0011$15.00 lance programs provide an excellent overview of rates of antimicrobial resistance in US hospitals [2 5, 8 13], these programs are extremely resource- and time-intensive and have important limitations. For example, most surveillance programs that track nosocomial pathogens are overrepresented by larger teaching hospitals [2, 14]. Fewer data exist from representative samples that include smaller and/or nonteaching hospitals. In addition, ongoing surveillance systems track overall rates of antimicrobial resistance; no existing program assesses the frequency of recognized outbreaks due to antimicrobial-resistant organisms in US hospitals. Finally, few data exist that describe the extent to which hospitals adhere to guidelines for the control of antimicrobial-resistant pathogens [15]. Several guidelines have been published [16 18], yet antimicrobial resistance rates continue to increase. Most recently, the Centers for Disease Control and Prevention (CDC; Atlanta, GA) unveiled a campaign with recommendations to prevent and control antimicrobial resistance [19]. We performed a large representative survey of US 78 CID 2004:38 (1 January) Diekema et al.
hospitals, stratified by the number of beds, geographic region, and teaching status. Specific goals of this study were (1) to estimate antimicrobial resistance rates and outbreak frequency associated with 4 epidemiologically important antimicrobialresistant pathogens, and (2) to investigate the extent to which hospitals adopt measures for prevention and control of antimicrobial resistance. MATERIALS AND METHODS Sample population. The American Hospital Association annual survey data set was used to identify the sample. Stratification variables were the number of beds (50 99 beds, 100 199 beds, and 200 beds), teaching status (member or nonmember of the Council of Teaching Hospitals), and geographic region (table 1). All acute care Veterans Affairs Medical Centers (VAMCs) were included, with 4 5 non-vamcs selected for each VAMC in these strata. Facilities were excluded if they had!50 beds, were not general medical and surgical, or were not accredited by the Joint Commission on Accreditation of Healthcare Organizations. The sample included 670 hospitals. Survey. The survey was mailed to the clinical microbiology laboratory director at each selected hospital. The mailing included the survey, a cover letter, and letters of support for the research (see Acknowledgments). The study procedures, cover letter, and questionnaire were approved by the University of Iowa institutional review board. A reminder postcard was mailed to nonresponders 3 4 weeks after the first survey mailing. A follow-up mailing, which included another survey and cover letter, was sent 4 6 weeks after the postcard mailing. Six weeks after the second survey mailing, nonresponders were contacted by phone and asked to participate. Fourteen weeks after the phone calls were made, a letter, accompanied by a 30- min phone card, was sent to respondents to thank them for their participation. Concurrently, a phone card and letter were sent to nonresponders, which served as a final incentive to participate. Survey development was informed by 2 pilot studies, the second of which included 108 hospitals nationally, to refine the questions and establish methods for reliably estimating resistance rates on an interval scale. The survey instrument addressed (1) prevalence (among all unique clinical isolates from both nosocomial and community onset infections, with duplicate patient isolates excluded) of oxacillin resistance among S. aureus (ORSA), vancomycin resistance among enterococci (VRE), ceftazidime resistance among Klebsiella species (K- ESBL), and quinolone (ciprofloxacin) resistance among Escherichia coli (QREC); (2) three-year trends in these resistances; (3) frequency of recognized outbreaks of these resistant pathogens; (4) availability, frequency, and distribution of reports on the occurrence of antimicrobial resistance (i.e., antibiograms); Table 1. Characteristics of 494 US acute care hospitals that participated in the survey. Characteristic No. (%) of hospitals (n p 494) Region New England/Mid-Atlantic 82 (16.6) East-North-Central/West-North-Central 119 (24.1) South Atlantic/East-South-Central/West-South-Central 199 (40.4) Mountain/Pacific 93 (18.9) No. of beds 50 99 49 (9.9) 100 199 115 (23.2) 200 329 (66.7) Member of Council of Teaching Hospitals 208 (42.2) Surrounding area with nonmetropolitan population base 97 (20.2) Veterans Affairs hospital 98 (19.8) (5) representation of the microbiology laboratory on the hospital infection-control committee; (6) promptness of notification of pertinent personnel when important resistances are detected; (7) time from bacterial isolation to susceptibility test reporting; and (8) extent of the hospitals implementation of measures to provide feedback on the occurrence of antimicrobial resistance, implement guidelines for antimicrobial use, recognize and promptly report trends in resistance, rapidly detect resistant pathogens in patient specimens, and provide appropriate resources to prevent resistance. Extent of hospital implementation and support for measures to control resistance was reported using a 5-point Likert scale ( not at all, very little, some, great, and very great ). All participants were asked to include their most recent antibiogram to allow for validation of reported resistance rates. Analyses. Point estimates for the overall resistance rates were calculated by the ridit method, using the range category reported by each facility to calculate an overall mean resistance rate for each organism [20]. Resistance rates were compared across geographic region, teaching status, and VA status using the Cochran-Mantel-Haenszel mean score statistic. Resistance rates were compared across bed number using the Jonckheere- Terpstra test [21], which measured the null hypothesis of no association between bed number and resistance rate. The significance level was set at.05, and all P values were 2-tailed. All statistical analyses were performed with SAS (SAS Institute) and StatXact (Cytel Software) software. RESULTS A total of 494 hospital laboratories (74%) responded. The characteristics of participating hospitals (table 1) were representative of the sampling frame. Almost two-thirds (64%) of hospitals included a copy of their antibiogram. Antimicrobial Resistance in US Hospitals CID 2004:38 (1 January) 79
Figure 1 shows the proportion of hospitals reporting various levels of epidemiologically important antimicrobial resistances among clinical isolates. Levels were highest for ORSA and lowest for K-ESBL. Overall point estimates of resistance rates were as follows: 36% of S. aureus were resistant to oxacillin, 10% of enterococci were resistant to vancomycin, 6% of E. coli were resistant to ciprofloxacin, and 5% of Klebsiella species were resistant to ceftazidime. Table 2 compares point estimates of resistance rates that we observed for the 4 marker antimicrobial resistant pathogens with antimicrobial resistance rates from several microbiological surveillance programs. The 2 programs with results that most closely approximated the data obtained in this survey, SENTRY and The Surveillance Network (which reported resistance rates for all [i.e., community and nosocomial] recently recovered clinical isolates), demonstrated resistance rates associated with the 4 antimicrobials that were remarkably close to our point estimates. Figure 2 summarizes resistance rates according to the stratification variables bed number, teaching status, and geographic region. Each resistance rate increased significantly as the number of beds increased. In addition, teaching hospitals reported significantly higher resistance rates than did nonteaching hospitals. The major regional differences in resistance included higher ORSA and QREC rates in the South, a higher rate of K-ESBL in the Northeast, and lower resistance rates (particularly for ORSA) in the Mountain/Pacific region. Table 3 summarizes the 3-year trends for each of the 4 antimicrobial resistances reported by participating hospitals and the percentage of participating centers that had reported an outbreak of one of the surveyed antimicrobial-resistant pathogens during the previous 5 years. ORSA was the pathogen that was most commonly associated with an increase in incidence, whereas the incidence of K-ESBL increased in the fewest hospitals. Less than 10% of hospitals reported a decreasing rate of resistance to any of the surveyed antimicrobials. ORSA was the most common antimicrobial-resistant pathogen to have caused recognized outbreaks, which had occurred in almost one-half of the participating centers during the previous 5 years. Outbreaks of VRE infection were also frequent, occurring in nearly one-third of the hospitals. Less than 10% of the centers had reported an outbreak of K-ESBL or QREC infection during the previous 5 years. Hospital clinical microbiology laboratories reported varying levels of support for antimicrobial resistance prevention and control efforts (table 4). More than 80% of laboratory directors reported that they regularly participate in infection-control committee meetings; 190% reported that they had developed and disseminated an antibiogram. More than 80% of the centers compiling antibiograms reported that they updated them at least yearly. Most hospital laboratories (78%) reported susceptibility test results within 24 h of bacterial isolation. More than 90% of laboratory directors reported notification of infection-control personnel immediately (by phone or page) when an epidemiologically important resistant pathogen (i.e., ORSA or VRE) was detected. Two-thirds reported prompt notification of both the attending physician and the nursing unit. The level of implementation of recommended measures to control resistance was highest for rapid detection of resistant organisms and was Figure 1. Rates of epidemiologically important antimicrobial resistances at 494 US hospitals participating in the survey 80 CID 2004:38 (1 January) Diekema et al.
Table 2. Comparison of the current survey results with other contemporary surveillance results for 4 marker antimicrobial-resistant pathogens. Pathogen Current a (n p 494) Antimicrobial resistance rates among unique clinical isolates, by surveillance system (n p number of hospitals surveyed) SENTRY b TSN c ICARE d NNIS e (n p 30) (n p 118) (n p 41) (n p 315) SCOPE f (n p 49) Oxacillin-resistant Staphylococcus aureus 36 34 37 33 55 29 Vancomycin-resistant enterococci 10 15 13 12 26 18 Ceftazidime-resistant Klebsiella species 5 5 7 4 11 13 Ciprofloxacin-resistant Escherichia coli 6 3 4 1 1 NOTE. ICARE, Intensive Care Antimicrobial Resistance Epidemiology; NNIS, National Nosocomial Infections Surveillance System; SCOPE, Surveillance and Control of Pathogens of Epidemiologic Importance; TSN, the Surveillance Network. a Represents primarily 1999 2001 isolates, nosocomial and community onset included. b Represents 1997 1999 isolates, nosocomial and community onset included [2, 9 11]. c Represents 2000 isolates, nosocomial and community onset included [12, 13], except 1995 1997 data for Enterococcus species [8]. d Represents 1996 1997 nosocomial isolates from intensive care unit (ICU) and general wards [5]. e Represents 2000 nosocomial ICU isolates only [3]. f Represents 1995 1998 nosocomial bloodstream isolates only [4]. lower for implementing guidelines for antimicrobial use, providing appropriate resources to prevent antimicrobial resistance, providing feedback on the occurrence of antimicrobial resistance, and reporting significant antimicrobial resistance trends (table 4). Antibiograms were submitted by 317 hospitals. The 4 monitored resistance rates obtained from the antibiograms were within 0 3 percentage points of reported rates for all combinations of organisms and antimicrobials (rates for antibiograms vs. survey reports, respectively, were as follows: ORSA, 39% vs. 36%; VRE, 11% vs. 10%; K-ESBL, 6% vs. 5%; and QREC, 6% vs. 6%). DISCUSSION The emerging threat of antimicrobial resistance has been well documented [2 13]. Using a large, stratified and representative sample, we established that very few US hospitals have been successful in halting or reversing the emergence of antimicrobial resistance especially among S. aureus, one of the most common and devastating human pathogens [22]. Moreover, resistant pathogens are frequently implicated in hospital outbreaks. The financial and human [22 25] costs associated with the unchecked spread of antimicrobial-resistant pathogens demand a more aggressive approach to prevention and control. Multiple recommendations have been developed to help prevent and control antimicrobial resistance [15 19, 26]. Any prevention and control recommendations must be based on reliable and valid surveillance that documents the extent and distribution of the problem of antimicrobial resistance. Surveillance will also prove important for monitoring the success of prevention and control efforts. Most large-scale antimicrobial resistance surveillance programs are labor intensive, and larger tertiary care hospitals are overrepresented [2, 14]. Although these programs provide highquality data, and some even provide central reference laboratory confirmation of antimicrobial susceptibility testing results [2], there is interest in using alternative surveillance methods that use electronic data transfer from laboratories [8] or hospitalderived antibiograms [27, 28] to estimate antimicrobial resistance rates. Using a survey of a large, stratified, random sample of US hospitals, we found that rates of important resistances closely approximated those reported from more labor-intensive surveillance programs. The comparability of our data with data generated from existing surveillance programs argues for the establishment of a nationwide reporting system for antimicrobial resistance and outbreak frequency. In addition, our data indicate a very high level of antibiogram preparation and relatively frequent updating of antibiograms. If confidentiality is assured and participation is relatively simple, such a system will be invaluable for tracking antimicrobial resistance trends and outbreak frequency in real time on national, regional, state, and local levels. This could be part of the proposed National Healthcare Safety Network, an internet-based reporting and information system in development by the CDC in collaboration with the Agency for Healthcare Research and Quality, the Centers for Medicare and Medicaid Services, and the US Food and Drug Administration (http://www.cdc.gov/ncidod/hip). Our survey also provides important data regarding temporal trends in antimicrobial resistance. As demonstrated by CDC investigators, using aggregate multicenter surveillance data to assess trends in antimicrobial resistance does not take into account outlier data and tends to overestimate increases in the prevalence of antimicrobial resistance [29]. Using conservative statistical methods that took into account changes within in- Antimicrobial Resistance in US Hospitals CID 2004:38 (1 January) 81
Figure 2. Rates of antimicrobial resistance, according to the following stratification variables: bed number (A; P!.0001, for difference in each resistance rate by hospital bed number); teaching status (B; P!.01, for difference in each resistance rate by teaching status); and geographic region (C; P p.0001, for difference in oxacillin-resistant Staphylococcus aureus [ORSA] by region, P p.04 for difference in ceftazidime-resistant Klebsiella species [K-ESBL] by region, P p.048 for difference in ciprofloxacin-resistant Escherichia coli [Q-REC] by region, and P p.2, no significant difference in vancomycin-resistant enterococci [VRE] by region [see text]). dividual hospitals, Fridkin et al. [29] found that significant increases in antimicrobial resistance in a sample of 23 hospitals were only noted for oxacillin resistance among S. aureus and for quinolone resistance among Pseudomonas aeruginosa and E. coli. In our survey, we asked each hospital for their antimicrobial resistance trends for epidemiologically important organisms. Our data suggest that previously described increasing trends in the frequency of ORSA infection [2, 3] are not because of data primarily from outlier hospitals. Rather, more than twothirds of this large stratified sample of hospitals report that the rate of oxacillin resistance among S. aureus is increasing, whereas!5% of hospitals report a decreasing trend. Although fewer hospitals (26% 48%) reported increasing trends in the other 3 resistances, it is discouraging to note that!10% of hospitals reported a decreasing trend for any of the resistances we examined. It seems clear that current practices to prevent and control antimicrobial resistance in hospitals are not working. Our survey represents a rare attempt to determine the frequency with which outbreaks of antimicrobial resistant pathogens occur in US hospitals [30, 31]. Although relatively few nosocomial infections are thought to be outbreak related [30, 31], when outbreaks do occur, they can result in substantial morbidity, mortality, and resource utilization. In addition, outbreaks are, by definition, special cause events and should be preventable. An outbreak, therefore, almost always reflects poorly on infection control and prevention practice in a hospital and can lead to a great deal of anxiety, turmoil, and unfavorable media attention [32]. Almost one-half of the hospitals surveyed had recognized an outbreak of ORSA infection during the 5 years before our survey, and almost 25% had recognized such an outbreak during the previous year. Although the frequency of outbreaks was lower for the other resistant pathogens, they nonetheless occurred commonly 1 in 4 hospitals reported an outbreak of VRE infection during the previous 5 years. Because outbreaks may not be recognized and often resolve without specific intervention [22], these data almost certainly underestimate the problem. Given the data we present with regard to rates of antimicrobial resistance and outbreak frequency, it is important to determine the extent to which hospitals have implemented guidelines recommended for antimicrobial resistance preven- 82 CID 2004:38 (1 January) Diekema et al.
Table 3. Trends in rates of resistance and outbreak frequency for 4 marker antimicrobial-resistant pathogens in a national sample of 494 US hospitals. Pathogen 3-year trend in resistance, % of hospitals Increasing Unchanged Decreasing Reported an outbreak, % of hospitals During the previous 5 years During the previous year Oxacillin-resistant Staphylococcus aureus 66 30 4 48 24 Vancomycin-resistant enterococci 48 43 9 31 12 Ceftazidime-resistant Klebsiella species 26 70 4 8 3 Ciprofloxacin-resistant Escherichia coli 40 59 2 5 3 tion and control. Previous work suggests that adoption of recommended antimicrobial use guidelines is inadequate [15]. However, our study represents the largest sample of hospitals surveyed to assess measures implemented to prevent and control antimicrobial resistance. These data suggest that most hospitals have implemented measures to detect and report antimicrobial resistance (on-site testing, rapid detection, and antibiogram with regular updating, etc.). However, fewer facilities report vigorous implementation of guidelines for antimicrobial use or provision of adequate resources for prevention Table 4. Antimicrobial resistance prevention and control efforts reported by 494 participating hospitals. Procedure or service No. (%) of hospitals Provides on-site antimicrobial susceptibility testing 463 (94) Microbiology laboratory director regularly participates on the infection control committee 401 (81) Compiles an antibiogram for use by clinicians 464 (94) Antibiogram update interval, months a 1 3 40 (9) 4 6 91 (20) 7 12 236 (51) 112 80 (17) Laboratory b Uses confirmatory tests to detect production of ESBLs 272 (59) Supervised by doctoral-level clinical microbiologist 188 (41) Makes molecular typing available for infection control use 168 (36) Likert scale analysis c Rapidly detects resistant microorganisms in individual patients 416 (87) Implements guidelines for important types of antimicrobial use 272 (60) Promptly reports significant trends in antimicrobial resistance 254 (56) Provides feedback on the occurrence of antimicrobial resistance 237 (53) Provides appropriate resources to prevent antimicrobial resistance 230 (53) and control efforts. More research is needed to assess in greater detail how current guidelines for prevention and control of antimicrobial resistance are implemented, monitored, and enforced. There are limitations to relying on self-report for surveillance of antimicrobial resistance. First, although the data may be accurate for common, clinically important resistances that interest laboratory directors and infection-control practitioners, the data may not be as accurate for early detection of emergingresistance phenotypes. Second, self-reported data not accom- NOTE. ESBL, extended spectrum b-lactamase. a Denominator includes only those 464 respondents who reported having compiled an antibiogram. b Denominator includes only those 463 respondents who reported having performed on-site susceptibility testing. c Answer of either a great or very great extent; denominator does not include missing responses. Antimicrobial Resistance in US Hospitals CID 2004:38 (1 January) 83
panied by central reference laboratory testing of the organisms does not allow for independent confirmation of the resistance phenotype or additional testing (e.g., molecular typing to examine genetic relatedness of strains and evidence of patientto-patient transmission). Third, self-reported data generally include all organisms tested in a laboratory (antibiogram data), rather than separating the data by nosocomial versus community acquisition. However, data from the CDC s Intensive Care Antimicrobial Resistance Epidemiology program suggest that, with the exception of ORSA, hospital antibiogram data closely approximate resistance rates among nosocomial pathogens [27]. The data we report have important implications. A more aggressive approach to the prevention and control of antimicrobial resistance is needed. Improved antibiotic utilization to limit selective pressure [33] and improved adherence to infection-control practices (especially hand hygiene [34, 35]) should form the bedrock of this approach. However, large multicenter trials to examine innovative approaches to control antimicrobial resistance (e.g., earlier detection, isolation, and/or decolonization of infected or colonized persons) are indicated. Acknowledgments We are grateful to laboratory directors at each participating hospital, for sharing data, and Dr. William Martone (National Foundation for Infectious Diseases, Bethesda, MD), Dr. Dale Gerding (Society for Healthcare Epidemiology of America, Mt. Royal, NJ), and Prof. Elaine Larson (Columbia University School of Nursing, New York, NY), for letters of support and advice. References 1. Centers for Disease Control and Prevention. 1992. Public health focus: surveillance, prevention and control of nosocomial infections. MMWR Morb Mortal Wkly Rep 1992; 41:783 7. 2. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the SENTRY Antimicrobial Surveillance Program, 1997 1999. Clin Infect Dis 2001; 32(Suppl 2): S114 32. 3. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 June 2001, issued August 2001. Am J Infect Control 2001;29: 404 21. 4. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29:239 44. 5. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in US hospitals: Project ICARE Phase 2. Clin Infect Dis 1999; 29:245 52. 6. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565 7. 7. Centers for Disease Control and Prevention. Public health dispatch: vancomycin resistant Staphylococcus aureus, Pennsylvania 2002. MMWR Morb Mortal Wkly Rep 2002; 51:902. 8. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database USA. Clin Infect Dis 1999; 29:259 63. 9. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum b-lactamase phenotype and characterization of isolates from Europe, the Americas and the Western Pacific region. Clin Infect Dis 2001; 32(Suppl 2): S94 103. 10. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997 1999. Clin Infect Dis 2001; 32(Suppl 2):S133 45. 11. Diekema DJ, Pfaller MA, Jones RN, Doern GV. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999; 29: 595 607. 12. Jones ME, Mayfield DC, Thornsberry C, et al. Prevalence of oxacillin resistance in Staphylococcus aureus among inpatients and outpatients in the United States during 2000. Antimicrob Agents Chemother 2002; 46:3104 5. 13. Karlowsky JA, Kelly LJ, Thornsberry C, et al. Susceptibility to fluoroquinolones among commonly isolated gram-negative bacilli in 2000: TRUST and TSN data for the US. Int J Antimicrob Agents 2002; 19: 231 31. 14. Richards C, Emori TG, Edwards J, et al. Characteristics of hospitals and infection control professionals participating in the National Nosocomial Infections Surveillance System 1999. Am J Infect Control 2001; 29:400 3. 15. Lawton RM, Fridkin SK, Gaynes RP, McGowan JE Jr. Practices to improve antimicrobial use at 47 US hospitals: the status of the 1997 SHEA/IDSA position paper recommendations. Society for Healthcare Epidemiology of America/Infectious Diseases Society of America. Infect Control Hosp Epidemiol 2000; 21:256 9. 16. Shlaes DM, Gerding DN, John JF, et al. Society for Healthcare Epidemiology and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25:584 99. 17. The Hospital Infection Control Practices Advisory Committee (HIC- PAC). Recommendations for preventing the spread of vancomycin resistance. Am J Infect Control 1995; 23:878 94. 18. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 1996; 275:234 40. 19. Centers for Disease Control and Prevention. Campaign to prevent antimicrobial resistance in healthcare settings. 2002. Available at: http: //www.cdc.gov/drugresistance/healthcare/default.htm. Accessed 3 December 2003. 20. Bross IDJ. How to use ridit analysis. Biometrics 1958; 14:18 38. 21. StatXact user manual. Version 5.0.3. Cambridge, MA: Cytel Software, 2000. 22. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus in New York City hospitals. Emerg Infect Dis 1999; 5:9 17. 23. Bach PB, Malak SF, Jurcic J, et al. Impact of infection by vancomycinresistant Enterococcus on survival and resource utilization for patients with leukemia. Infect Control Hosp Epidemiol 2002; 23:471 4. 24. McGowan JE. Economic impact of antimicrobial resistance. Emerg Infect Dis 2001; 7:286 92. 25. Institute of Medicine. Antimicrobial drug resistance: issues and options. Workshop report. Washington, DC: National Academy Press, 1998. 84 CID 2004:38 (1 January) Diekema et al.
26. American Society for Microbiology. Report of the ASM Task Force on antibiotic resistance. Antimicrob Agents Chemother 1995; (Suppl): 1 23. 27. Fridkin SK, Edwards JR, Tenover FC, et al. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin Infect Dis 2001; 33:324 30. 28. Chin AE, Hedberg K, Cieslak PR, Cassidy M, Stefonek KR, Fleming DW. Tracking drug-resistant Streptococcus pneumoniae in Oregon: an alternative surveillance method. Emerg Infect Dis 1999; 5:688 93. 29. Fridkin SK, Hill HA, Volkova NV, et al. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002;8: 697 701. 30. Wenzel RP, Thompson RL, Landry SM, et al. Hospital-acquired infections in intensive care unit patients: an overview with emphasis on epidemics. Infect Control 1983; 4:371 5. 31. Haley RW, Tenney JH, Lindsey JO, Garner JS, Bennett JV. How frequent are outbreaks of nosocomial infection in community hospitals? Infect Control 1985; 6:233 6. 32. Berens MJ. Infection epidemic carves deadly path. Chicago Tribune. 21 July 2002:A1. 33. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000; 21:455 8. 34. Pittet D, Hugonnet S, Harbath S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet 2000; 356:1307 12. 35. Centers for Disease Control and Prevention. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Preactices Committee and the HICPAC/SHEA/APIC/ IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of American/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51(RR- 16):1 45, quiz CE1 4. Antimicrobial Resistance in US Hospitals CID 2004:38 (1 January) 85